NAUT — Nautilus Biotechnology Cashflow Statement
0.000.00%
Last trade - 00:00- $418.30m
- $314.89m
Annual cashflow statement for Nautilus Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -50.3 | -57.9 | -63.7 | -70.8 | -59 |
| Depreciation | |||||
| Non-Cash Items | 10.1 | 11.7 | 13.3 | 15.1 | 10.1 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.022 | -0.788 | -3.22 | -5.46 | -3.58 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -39.2 | -45.8 | -51.7 | -59.1 | -50.7 |
| Capital Expenditures | -2.27 | -2.32 | -2.44 | -2.12 | -1.28 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -137 | -23.4 | -41.3 | 68.4 | 36.5 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -139 | -25.7 | -43.7 | 66.3 | 35.2 |
| Financing Cash Flow Items | 327 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 327 | 0.562 | 0.368 | 1.14 | 0.214 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 149 | -71 | -95.1 | 8.25 | -15.3 |